Paul W. Hoelscher
CIK 1611468 · EVP, CFO · last filed 2026-06-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
HZNP price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
C/O HORIZON THERAPEUTICS, INC.
DEERFIELD, IL 60015
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SGMT | Director | — | $9.56 | — | $0 | 4 | 2026-06-15 |
| OnKure Therapeutics, Inc. (RPHM) Delisted | Director | — | $18.20 | — | $0 | 3 | 2023-06-08 |
| Horizon Therapeutics Public Ltd Co (HZNP) Delisted | EVP, CFO | 89,264 | $116.30 | $10.38M | -$62.93M | 35 | 2022-04-22 |
Recent Filings · Page 3 of 5
42 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-02-28 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Gift (G) | — | $0 | EDGAR |
| 2020-02-21 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Mixed | +8,358 | -$239.8K | EDGAR |
| 2020-01-23 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Mixed | +3,094 | -$94.1K | EDGAR |
| 2020-01-07 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Mixed | +86,733 | -$2.50M | EDGAR |
| 2019-10-17 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Sell (S) | −20,000 | -$560.1K | EDGAR |
| 2019-09-04 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Sell (S) | −1,359 | -$38.1K | EDGAR |
| 2019-08-23 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Mixed | −41,327 | -$1.49M | EDGAR |
| 2019-03-25 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Mixed | +17,267 | -$368.6K | EDGAR |
| 2019-02-22 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Mixed | +40,311 | -$690.7K | EDGAR |
| 2019-01-08 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Mixed | +36,276 | -$599.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.